Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 11—November 2005
Research

Cryptococcus gattii in AIDS Patients, Southern California

Sudha Chaturvedi*†, Madhu Dyavaiah*, Robert A. Larsen‡§, and Vishnu Chaturvedi*†Comments to Author 
Author affiliations: *Wadsworth Center, Albany, New York, USA; †State University of New York, Albany, Albany, New York, USA; ‡University of Southern California, Los Angeles, California, USA; §Los Angeles County Hospital, Los Angeles, California, USA

Main Article

Figure 2

Multiplex polymerase chain reaction (PCR) for pheromone fragment analysis. A) Multiplex PCR with 4 sets of primers comprising MFα1 (V190/V191) and MFa1 (V290/V291, V1311/V1312, V1313/V1314) genes were carried out as described in Materials and Methods. Approximately 100-bp MFα1 and 117-bp MFa1 PCR amlicons were detected on 3.5% MetaPhor agarose in Tris-borate-EDTA buffer for MATα and MATa strains comprising Cryptococcus neoformans var. grubii (CnVG), Cryptococcus neoformans var. neoformans (CnVN)

Figure 2. Multiplex polymerase chain reaction (PCR) for pheromone fragment analysis. A) Multiplex PCR with 4 sets of primers comprising MFα1 (V190/V191) and MFa1 (V290/V291, V1311/V1312, V1313/V1314) genes were carried out as described in Materials and Methods. Approximately 100-bp MFα1 and 117-bp MFa1 PCR amlicons were detected on 3.5% MetaPhor agarose in Tris-borate-EDTA buffer for MATα and MATa strains comprising Cryptococcus neoformans var. grubii (CnVG), Cryptococcus neoformans var. neoformans (CnVN), and Cryptococcus gattii (Cg). Lanes 1 and 7, molecular mass marker. B) Multiplex PCR depicting MFα1 and MFa1 PCR amplicons from the 8 known hybrid (A/D) isolates. Lane 1, molecular mass marker.

Main Article

Page created: February 17, 2012
Page updated: February 17, 2012
Page reviewed: February 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external